Periarticular injection of liposomal bupivacaine in total knee arthroplasty.
The purpose of this study was to determine whether the use of a periarticular injection using liposomal bupivacaine could decrease pain and improve outcomes after total knee arthroplasty. Fifty consecutive patients received no periarticular injections (group A). Another 50 consecutive patients received a periarticular injection of liposomal bupivacaine (group B). There were no differences in the groups with respect to gender, age, body mass index (BMI), or comorbidities. There was a significant reduction in the amount of narcotics used in the liposomal bupivacaine group (60.97-mg oral morphine equivalent vs 89.74 mg,P= 0.009). Patients in group B with a BMI <40 and a Charlson comorbidity index of 0-3 had decreased length of stay (2.64 vs 3.06 days,P= .004), narcotic use over 24-48 hours (110.66 vs 182.47 mg,P= .013), and narcotic use over 48-72 hours (49.61 vs. 112.65 mg,P= .004). In patients with a BMI <40 and comorbidity index of ≤3, periarticular injection using liposomal bupivacaine leads to earlier discharge along with decreased use of narcotics.
KentuckyOne Health, Louisville, KY, USA.
Bradley T
BT
Webb
KentuckyOne Health, Louisville, KY, USA.
J Reid
JR
Spears
KentuckyOne Health, Louisville, KY, USA.
Langan S
LS
Smith
KentuckyOne Health, Louisville, KY, USA.
Arthur L
AL
Malkani
Liposomal bupivacaine; Pain; Postoperative; Total knee arthroplasty